ALI TEHRANI

Currently, Ali Tehrani serves as the CEO and Co-Founder of DCx Biotherapeutics. Prior to this, Ali co-founded Zymeworks and held the positions of President, Chief Executive Officer, and Board of Directors member from the company’s inception in September 2003 until January 2022. During his tenure, he guided the company through numerous pivotal milestones, including an initial public offering on the New York Stock Exchange in 2017, the establishment of nine partnerships with major pharmaceutical and biotechnology firms, and the advancement of multiple antibody therapeutics into clinical trials. Notably, in November 2024, Zymeworks’ Zanidatamab received approval from the US FDA for the treatment of biliary tract cancer.

Following his time at Zymeworks, Ali Tehrani joined Amplitude Ventures as a Partner, where he supported portfolio companies and contributed to company creation efforts, ultimately leading to the founding of DCx. Ali Tehrani holds both Bachelor’s and Master’s of Science degrees in biochemistry from the University of Massachusetts, and earned a Doctoral degree in microbiology and immunology from the University of British Columbia.